1Hadziyannis SJ;Sene H Jr;Morgan TR.Pegintefferonalpha2a and ribavirin combination therapy in chronic hepatitis C:a randomized study of treatment duration.and ribavirin dose[J],2004(05).
2Forestier N;Reesink HW;Weegink CJ.Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C[J],2007(03).
3Lee WM;Dienstag JL;Lindsay KL.Evolution of the HALT-C trial:pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonrespanders[J],2004(05).
4Patton HM;Patel K;Behling C.The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients[J],2004(03).
5Chung RT;Andersen J;Volberding P.Pegiaterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons[J],2004(05).
6Anand BS;Currie S;Dieperink E.Alcohol use and treatment of hepatitis C vires:results of a national muhicentor study[J],2006(06).
7Sethi A;Shiffman ML.Approach to the management of patients who failed to achieve sustained virologic response[J],2005(03).
8Strader DS;Wright T;Thomas DL.AASLD practice guideline:diagnosis,managemani,and treatment of hepatitis C[J],2004(04).
9Davis GL;Wong JB;McHutchison JG.Early virologic response to treatment with pegintederon alfa-2b plus rihavirin in patients with chronic hepatitis C[J],2003(03).
10Ferrenci P;Fried MW;Shiffman ML.Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin[J],2005(03).
